Dr. Matulonis Discusses QoL Data from GOG-258 in Endometrial Cancer

Ursula A. Matulonis, MD
Published: Thursday, Aug 16, 2018



Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the quality-of-life (QoL) outcomes from the GOG-258 trial in patients with endometrial cancer.

GOG-258 was a randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel versus carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. This trial included patients with stage III and stage IVA disease.

Matulonis says that in both groups, patients experienced significant neuropathy, which was attributed to the chemotherapy given. Patients who received radiation had more gastrointestinal toxicities, which were present at the 1-year mark. Matulonis says that these are important factors to consider when selecting therapy.


Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the quality-of-life (QoL) outcomes from the GOG-258 trial in patients with endometrial cancer.

GOG-258 was a randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel versus carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. This trial included patients with stage III and stage IVA disease.

Matulonis says that in both groups, patients experienced significant neuropathy, which was attributed to the chemotherapy given. Patients who received radiation had more gastrointestinal toxicities, which were present at the 1-year mark. Matulonis says that these are important factors to consider when selecting therapy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Redefining Ovarian Cancer Treatment Paradigms by Maximizing Therapeutic Outcomes with PARP InhibitorsSep 29, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x